Psychedelic Business Spotlight: July 16, 2021
This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.
mdma
Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has “discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about.”
How The Multidisciplinary Association for Psychedelic Studies Is Changing Mental Health Treatment
The Multidisciplinary Association for Psychedelic Studies has been studying mental health treatment for more than 35 years. Here’s what to know.
Promising Results from First Phase-3 Trial Investigating MDMA-Assisted Therapy for PTSD
The first phase-3 trial of its kind investigating MDMA for PTSD is showing promising results.
Study Investigates Optimal Dosing for MDMA
Potential optimal MDMA dosages for therapeutic benefit and reduced adverse events were investigated in a new study published in the latest edition of the Journal of Psychopharmacology.
U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction
Awakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol use disorder.
Minority Veterans Organization Urges Congress to Loosen Restrictions on Psychedelic Therapies
A minority veterans organization wants access to psychedelic therapies for PTSD and depression. It’s urging Congress to take action.
Charley Wininger Hopes to Normalize MDMA With New Book ‘Listening to Ecstasy’
In his book ‘Listening to Ecstasy’ psychoanalyst and mental health counselor Charley Wininger discusses MDMA’s benefits, including in his own marriage.
End of content
End of content